Compare ABR & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | BBNX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.7M | 897.6M |
| IPO Year | 2003 | 2025 |
| Metric | ABR | BBNX |
|---|---|---|
| Price | $1.27 | $16.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $2.25 | ★ $25.10 |
| AVG Volume (30 Days) | ★ 9.1M | 1.1M |
| Earning Date | 10-30-2026 | 10-27-2026 |
| Dividend Yield | ★ 72.31% | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $25.22 |
| Revenue Next Year | N/A | $47.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $1.28 | $8.80 |
| 52 Week High | $9.30 | $32.71 |
| Indicator | ABR | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 14.22 | 45.41 |
| Support Level | N/A | $15.40 |
| Resistance Level | $5.38 | $18.20 |
| Average True Range (ATR) | 0.15 | 1.62 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 0.28 | 25.71 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.